{"name":"Antibe Therapeutics Inc.","slug":"antibe-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ATB-346 standard dose","genericName":"ATB-346 standard dose","slug":"atb-346-standard-dose","indication":"Treatment of osteoarthritis","status":"phase_2"},{"name":"ATB-346 low dose","genericName":"ATB-346 low dose","slug":"atb-346-low-dose","indication":"Treatment of osteoarthritis","status":"phase_2"},{"name":"ATB-346 mid-dose","genericName":"ATB-346 mid-dose","slug":"atb-346-mid-dose","indication":"Treatment of osteoarthritis","status":"phase_2"}]}],"pipeline":[{"name":"ATB-346 standard dose","genericName":"ATB-346 standard dose","slug":"atb-346-standard-dose","phase":"phase_2","mechanism":"ATB-346 is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.","indications":["Treatment of osteoarthritis"],"catalyst":""},{"name":"ATB-346 low dose","genericName":"ATB-346 low dose","slug":"atb-346-low-dose","phase":"phase_2","mechanism":"ATB-346 low dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.","indications":["Treatment of osteoarthritis"],"catalyst":""},{"name":"ATB-346 mid-dose","genericName":"ATB-346 mid-dose","slug":"atb-346-mid-dose","phase":"phase_2","mechanism":"ATB-346 mid-dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.","indications":["Treatment of osteoarthritis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-03-19","type":"deal","source":"medicaldialogues.in","summary":"Sun Pharma subsidiary acquires Antibe Therapeutics for Rs 27 crores - medicaldialogues.in","headline":"Sun Pharma subsidiary acquires Antibe Therapeutics for Rs 27 crores","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQY0MwYlpDR19iNU13Q1pUUzNGTkNrQ1FlSl95U1JUSTR2bTVmbHRDYm9SR2FIRnNzSlJuX085UWl0cjVmaEd6aUVBdWlKY3ZLZUtld2xXS2M0aUhKNHpUSWVPSnRkU1RaMzl3d05zalY1aU03S1JNZnpCckdEMG5QMFdIcWdqWHVuZ0ZMbzF5am53QQ?oc=5","date":"2025-01-20","type":"deal","source":"The Pharma Letter","summary":"Taro to acquire 100% stake in Antibe Therapeutics - The Pharma Letter","headline":"Taro to acquire 100% stake in Antibe Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZ1dRWnJPZVZZc3FnYmNrRlBGYVBuOUZ3S3BMR2ZCTVpMQ2VOT1I3TUpTcWpHRk1iRnUwcy01LUgyOWpiM0F1dmdwWW13UW9PWmNDV2JuSGVDYm9JOWVSOGNTbHc4SUpUeHpTQm80Sll5Y3B4MWtxd2JLbkNjS3AwTXdHY2hCdE0?oc=5","date":"2025-01-19","type":"deal","source":"pharmaphorum","summary":"Sun Pharma unit poised to buy Canadian biotech Antibe - pharmaphorum","headline":"Sun Pharma unit poised to buy Canadian biotech Antibe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNc1NTa3pTZWd6bUpLdmpCNmEzTElMdjZPc2Y2T0tySEhnaGFYNXNFdk1GZWZfUzU4emFlLXg2UUYwVnM5WTFIdmlid3R3a0tYUnM4ZnZIQmhISEwzOWJIY0RfaWRLaVNPWjlraHc4V2ZfQ3Q5dE1ETDhyQjJWaXhPTC0wbHZIbHpycUo1WmhzSWxkR2NGTWZGeFpTdlVVbU9SbTBiNFhMR2VfQkN0cEFpV29OX2NEOUoyUlI5Ug?oc=5","date":"2025-01-17","type":"deal","source":"BW Healthcare World","summary":"Sun Pharma to Acquire 100 Per cent Stake in Canada’s Antibe Therapeutics - BW Healthcare World","headline":"Sun Pharma to Acquire 100 Per cent Stake in Canada’s Antibe Therapeutics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-16","type":"deal","source":"The Hindu","summary":"Sun Pharma to acquire Canadian clinical stage biotech firm Antibe Therapeutics - The Hindu","headline":"Sun Pharma to acquire Canadian clinical stage biotech firm Antibe Therapeutics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-16","type":"deal","source":"Business Standard","summary":"Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics - Business Standard","headline":"Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-16","type":"deal","source":"CNBC TV18","summary":"Sun Pharma unit Taro to acquire 100% stake in Antibe Therapeutics for an undisclosed sum - CNBC TV18","headline":"Sun Pharma unit Taro to acquire 100% stake in Antibe Therapeutics for an undisclosed sum - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOSmRUWDBxMGdnMTJSV2RHQTljOV9kYlhtS0tXV0loWjNkNmFGWDNhaC1ZMHk4SmhTUjVkZkhFQXctSWkzbW9ZMWpMemJXTGVQeW5tTXg5ZWNnYXBUNERjLXlVWWJRZEJUWTBKX2t4Zm9YdC1PN2pZMmtpQ0NwREozdkFBMlhaaGhJMnhQWFdR0gGTAUFVX3lxTE0tMkZNU0wwdVpIN29nUGJqUi1OOEhJLW9oT1pOMDB5NVg0T3dxdjNkV1RHZmpHbEV5elVSOEtzTk9nZ1BlcFZZanRLRWVxcEx4ZklVeUMxNjhzcDgxNHZsd0p5QnhidUhlY180RGZNelc4aFVxZzZlcl9NOWtlOVJkdVNlVkI5TkZ2STg0TDVvdTlvbw?oc=5","date":"2025-01-16","type":"deal","source":"Express Pharma","summary":"Sun Pharma subsidiary Taro acquires Antibe Therapeutics - Express Pharma","headline":"Sun Pharma subsidiary Taro acquires Antibe Therapeutics","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-16","type":"deal","source":"medicaldialogues.in","summary":"Sun Pharma arm Taro Pharma to acquire 100% stake in Antibe Therapeutics - medicaldialogues.in","headline":"Sun Pharma arm Taro Pharma to acquire 100% stake in Antibe Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxPejRGZWJpTmZNNWVJdm9YTHBrVk5xakRVV1NsbVhjQUxiVm9rbTc5OXBkMUpfVmRGMW9MOFpCcUliakR0emU4UjBrWUNIZWZQRlhoVEU1ODhHUWcxOGdkY3hIektmaGRoVDJMX1hTSllXTnBjbi1qYlE3cHY5QTN1SW1VcHpnc1NJbDdpcElkZW5JbmNiZ24taE5sVWRWZ0VIVkNYOHdvSTZXYVpKOXZDSFpNLVFlOEZJaFFxQkFLckM4WlA1aTJwT01XcW4xREsya0JYT1JJcHRHYmJwMExJNzRmeEYzZU1kTVNNdm5kVUlzN2xvcEJpWG8wNnBoU000N2Z4N2FvSU5pY29zeVFHNkVMbUU3RzhSbFh0a0hQNVE0eVFOQk4wdjBZYlg?oc=5","date":"2024-08-15","type":"pipeline","source":"GlobeNewswire","summary":"Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire","headline":"Global Non-Steroidal Anti-Inflammatory Drugs Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOMDNKeU93bHFLWnVwTzBGYWNPZ0pXS2pxZ3V2Qi1nMDJmN1B4UVBhclp3Sk15WkZjUmF3Y0MtNHFhRHNMbUNWT3hMLV9nWkM0YmhMcXg5bEtrNnpZR2tMRVBfbVMxRExtdXpNOU1vOWs4VXZ1UE9vWFVhQ2dha1RvRGtMLWdsNUtyR1dtalhweGtrTHpBajM5S00tVUlhMnZWSUV2Z1loOU1xWUJyNzJVX1Z6bFNXUTdITVhjdHFjaUdGdWYwRklaR3hrT0JDLUtPMDltSjdTR0FFaTRyVXlocUhR?oc=5","date":"2024-04-22","type":"regulatory","source":"Canadian Lawyer Mag","summary":"Fasken, Stikeman Elliot, TGF act in commercial cases worth $350–500 million - Canadian Lawyer Mag","headline":"Fasken, Stikeman Elliot, TGF act in commercial cases worth $350–500 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZk5yVUxjRl9GTG02dGZmd0dnODFZN1J1OUF2aTltY3M0UTM1YS01LXd6UXh0MnFmNTFIS0cyMEh4MDc1ZDJTT2l1ZlF2elY2bEdua0o5YnR4U1g3REdINHMtZ05HXzY3ZUJPRWFkZy1jQ0VLa3RsLXlsdlFSR2tCby1VVDRjYkUzbjU1TUhiQS1XNWt4Qm00Z2hUdzhTRXFiZWMwNDdVMjZEcnRTSjhmOXVEcVJxZm5BcnRPTmhEbmR3R2NuWFdQakFGUzBSWVdXRHJBSF9CRkxTLXdGVWZzaQ?oc=5","date":"2021-02-23","type":"pipeline","source":"Proactive financial news","summary":"Universal Ibogaine taps biopharmaceutical veteran Dr Rami Batal as its new CEO - Proactive financial news","headline":"Universal Ibogaine taps biopharmaceutical veteran Dr Rami Batal as its new CEO","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}